Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease
Diabetic kidney disease is a frequent microvascular complication of diabetes and is currently the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Although the prevalence of other complications of diabetes is falling, the number of diabetic patients with end-stage kidn...
Saved in:
Main Authors: | Nejc Piko (Author), Sebastjan Bevc (Author), Radovan Hojs (Author), Robert Ekart (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of Oxidative Stress in Kidney Injury
by: Nejc Piko, et al.
Published: (2023) -
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021) -
Oxidative Stress Markers in Chronic Kidney Disease with Emphasis on Diabetic Nephropathy
by: Nina Vodošek Hojs, et al.
Published: (2020) -
Albuminuria is Associated With Subendocardial Viability Ratio in Chronic Kidney Disease Patients
by: Robert Ekart, et al.
Published: (2015) -
Administration of finerenone in chronic kidney disease
by: Mohsen Akhavan Sepahi, et al.
Published: (2023)